Notice of Interim Results
Cambridge, UK and Indianapolis, US - 31 August 2018: Acacia Pharma Group plc ("Acacia Pharma", the "Company" or the "Group"), (EURONEXT: ACPH), today announces that the Company will issue its interim results for the six-month period ended 30 June 2018 on Friday 7 September 2018.
A conference call will take place on the same date at 14:00 CEST. Dr. Julian Gilbert, CEO and Christine Soden, CFO will present the financial and operational results followed by a Q&A session.
The dial-in numbers for the conference call are:
Belgium: 0800 746 68
Netherlands: 0800 022 9132
UK Toll Free: 0808 109 0700
USA Toll Free: +1 866 966 5335
Standard International Access: +44 (0) 20 3003 2666
The call Password is Acacia.
ACACIA PHARMA GROUP PLC
DR. JULIAN GILBERT, CEO
Acacia Pharma Group plc
Julian Gilbert, CEO
Christine Soden, CFO
+44 1223 919760
Citigate Dewe Rogerson (Financial PR)
Mark Swallow, Shabnam Bashir, David Dible
+44 20 7638 9571
About Acacia Pharma
Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialisation of new nausea & vomiting treatments for surgical and cancer patients. The Group has identified important and commercially attractive unmet needs in nausea & vomiting and has discovered two product candidates based on the same active ingredient, amisulpride, to meet those needs.
The Group's lead project, BARHEMSYS(TM) (amisulpride injection) for post-operative nausea & vomiting (PONV), has successfully completed Phase 3 clinical studies and an NDA is under review by the US FDA for marketing approval. Its sister project, APD403 for chemotherapy induced nausea & vomiting (CINV) has successfully completed one proof-of-concept and one Phase 2 dose-ranging study in patients receiving highly emetogenic chemotherapy.
Acacia Pharma is based in Cambridge, UK and its US operations are centred in Indianapolis, IN. The Company is listed on the Euronext Brussels exchange under the under ISIN code GB00BYWF9Y76 and ticker symbol ACPH. www.acaciapharma.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Acacia Pharma Group plc via GlobeNewswire